Retinoblastoma Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Market is segmented by Treatment Type, Type of Retinoblastoma (Non-hereditary Retinoblastoma, and Hereditary Retinoblastoma), Type of Staging, and Geography

Retinoblastoma Treatment Industry Overview

Retinoblastoma Treatment Market Size
Study Period: 2018 - 2028
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.56 %

Major Players

Retinoblastoma Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Retinoblastoma Treatment Market Analysis

The global retinoblastoma treatment market size is expected to grow at a CAGR of 4.56% over the forecast period. The market is projected to exhibit moderate growth over the forecast period, which can be attributed to factors such as remission and the chance of recurrence, and increasing public awareness.

Recurrent retinoblastoma occurs, when cancer comes back after it has been treated and diagnosed. Both extraocular and intraocular retinoblastoma might have probable chances of remittance.

In addition, improving awareness about retinoblastoma is a worthwhile goal, and any eye complaint merits careful attention from all nursing and medical personnel. Improving awareness regarding retinoblastoma is especially important in developing countries, as the incidences of eye cancer are increasing, and many children die undiagnosed or have advanced disease at presentation, due to delay in referral to an oncology centre. Retinoblastoma educational and public awareness campaigns have been shown to increase referrals, decrease rates of advanced disease, and improve outcomes in low and middle-income countries.

However, side effects of retinoblastoma surgery, radiation therapy to the head and certain chemotherapy drugs, such as cisplatin and carboplatin (Paraplatin, Paraplatin AQ), may cause hearing loss when they are given to very young children.

Retinoblastoma Treatment Industry Segments

Retinoblastoma is the most common cancer among children, which starts in the retina. It generally develops before the age of 5. One out of three children with retinoblastoma develops cancer in both eyes. The most common symptom of retinoblastoma is a visible whiteness in the pupil, called cat's eye reflex or leukocoria. As per the scope of the report, the retinoblastoma tretament market is sub divided into treatment type, type of retinoblastoma, type of staging and geography.

By Treatment Type
Radiation therapy
Laser Therapy (Photocoagulation)
Opthalmic Artery Infusion Chemotherapy
High-dose Chemotherapy and Stem Cell Transplant
By Type of Retinoblastoma
Non-hereditary Retinoblastoma
Hereditary Retinoblastoma
By Type of Staging
Intraocular Retinoblastoma
Extraocular Retinoblastoma
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Retinoblastoma Treatment Market Trends

This section covers the major market trends shaping the Retinoblastoma Treatment Market according to our research experts:

Non-hereditary Retinoblastoma is Expected to hold its Highest Market Share in the Retinoblastoma Type Segment

The non-hereditary retinoblastoma (NHR) segment is expected to have the largest market size and is expected to continue the same during the forecast period

Non-hereditary retinoblastoma (NHR), also known as sporadic retinoblastoma, is the more prevalent form of retinoblastoma. According to the American Cancer Society, 67% of reported cases (in the United States) of retinoblastoma in pediatrics are non-hereditary or sporadic.

The NHR is mostly a pediatric disease, and according to the American Cancer Society, the survival rates post diagnosis is approximately 90%. According to the Union for International Cancer Control, the average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately one in 14,000 – 18,000 live births).

The market for NHR is expected to grow tremendously over the forecast period, primarily due to the higher incidence rate, when compared to hereditary retinoblastoma. Additionally, factors, like high survival rates post diagnosis in developed regions, like the United States, are likely to add to the global market growth.

Retinoblastoma Treatment Market Analysis

Asia-Pacific Dominates the Market and Expected to do Same in the Forecast Period

Asia-Pacific currently dominates the market for Retinoblastoma Treatment and is expected to continue its strong hold for a few more years. This region is expected to increase its market share in the future owing to the fact that, retinoblastoma (Rb) is the most common primary intraocular malignancy of infancy and childhood, and seriously endangers the vision and life of children.

According to the United Nations Survey in 2016, China was only second to that in India, in the prevalence of Rb in APAC countries. Similarly, according to the Japanese Journal of Ophthalmology, in 2018, the average occurrence frequency for retinoblastoma was 1:16,823 births/year and at diagnosis, 89.0% of the patients were aged younger than 3 years and 41.0% were aged younger than 1 year.

Furthermore, in countries like India, current treatment modalities of systemic chemotherapy and focal treatment have contributed significantly to disability limitation and patient survival and there is less knowledge on the genetics of the retinoblastoma gene and its protein, and there is potential for developing targeted molecular therapies.

Retinoblastoma Treatment Industry

Retinoblastoma Treatment Market Competitor Analysis

The Retinoblastoma Treatment market is moderately competitive and consists of a considerable number of major players. Companies like B Baxter International Inc., GlaxoSmithKline, Pfizer Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, Merck & Co., Cadila Pharmaceuticals, and Teva Pharmaceutical, among others, are expected to hold the substantial market share in the Retinoblastoma Treatment market.

Retinoblastoma Treatment Market Top Players

  1. Baxter International, Inc.

  2. GlaxoSmithKline PLC

  3. Pfizer, Inc.

  4. Johnson & Johnson

  5. Novartis AG

*Disclaimer: Major Players sorted in no particular order

Baxter International, Inc., GlaxoSmithKline PLC, Pfizer, Inc., Johnson & Johnson, Novartis AG

Retinoblastoma Treatment Market Report - Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Remission and the Chance of Recurrence

      2. 4.2.2 Increasing Public Awareness

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Retinoblastoma Surgery

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment Type

      1. 5.1.1 Surgery

      2. 5.1.2 Radiation therapy

      3. 5.1.3 Laser Therapy (Photocoagulation)

      4. 5.1.4 Cryotherapy

      5. 5.1.5 Thermotherapy

      6. 5.1.6 Chemotherapy

      7. 5.1.7 Opthalmic Artery Infusion Chemotherapy

      8. 5.1.8 High-dose Chemotherapy and Stem Cell Transplant

    2. 5.2 By Type of Retinoblastoma

      1. 5.2.1 Non-hereditary Retinoblastoma

      2. 5.2.2 Hereditary Retinoblastoma

    3. 5.3 By Type of Staging

      1. 5.3.1 Intraocular Retinoblastoma

      2. 5.3.2 Extraocular Retinoblastoma

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Baxter International Inc.

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Cadila Pharmaceuticals

      4. 6.1.4 GlaxoSmithKline plc

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Merck & Co.

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Teva Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Retinoblastoma Treatment Market Research FAQs

The Retinoblastoma Treatment Market is studied from 2018 - 2028.

The Retinoblastoma Treatment Market is growing at a CAGR of 4.56% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2018 - 2028.

North America holds highest share in 2021.

Baxter International, Inc., GlaxoSmithKline PLC, Pfizer, Inc., Johnson & Johnson, Novartis AG are the major companies operating in Retinoblastoma Treatment Market.

Retinoblastoma Treatment Industry Reports

In-depth industry statistics and market share insights of the Retinoblastoma Treatment sector for 2020, 2021, and 2022. The Retinoblastoma Treatment research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Retinoblastoma Treatment report PDF.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!